Skip to main content
LH logo

Labcorp Holdings Inc. (LH) Stock: Price, Forecast & Analyst Target

Labcorp Holdings Inc. (LH) — MoonshotScore 71/100 (Strong band), calculated Nov 18, 2026. Price $370.78 (+0.69%), as of the Nov 18, 2026 trading session; market cap $30.1B. Expected results Feb 16, 2027.

Educational signal · not a buy or sell recommendation · How to read this

$370.78 +$2.54 (+0.69%) Market Cap $30.1B

Labcorp Holdings Inc. · LH · NYSE · Healthcare · Medical - Diagnostics & Research

Research dated 2026-09-12: Labcorp sells diagnostic and research laboratory services to clinicians, healthcare facilities, drug developers, investigators, and patients; it is not merely a manufacturer of laboratory tests. The case rests on whether rising laboratory demand and improving profit conversion can outweigh heavy debt and the sharp contraction in readily available cash.

Price as of Nov 18, 2026

Key Statistics

71 of 100

MoonshotScore v2 · Labcorp Holdings (LH)

Strong
Business Quality Solid (76)
Financial Safety Okay (40)
Valuation Fair (60)
Growth Durability Flat (48)
Momentum Surging (92)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality, though the balance sheet and growth are only middling; the market is already moving on it. Business Quality: Solid; Financial Safety: Okay; Valuation: Fair; Growth Durability: Flat; Momentum: Surging.

  • EPS beat 0 of the last 4 reports
  • expected results Feb 16, 2027
  • Altman Z 3.54 · Piotroski F 8

Helping: business quality, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for LH (57 recorded, newest six shown)
RecordedScoreBand
73Strong
73Strong
73Strong
73Strong
71Strong
71Strong

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$370.78
Change on the day+0.69%
52-week range$245.00–$375.10
Market capitalisation$30.1B—
Price / earnings (trailing)30.01
Shares traded on the day689.9K
Beta (volatility vs the S&P 500)0.84

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 18, 2026: low $250, high $371, latest $371. $371 $250 high $371 Oct 17, 2025 Nov 18, 2026 · $371 $286Oct 17, 2025$254Oct 31, 2025$267Nov 14, 2025$269Nov 28, 2025$264Dec 12, 2025$254Dec 26, 2025$252Jan 9, 2026$267Jan 23, 2026$277Feb 6, 2026$283Feb 20, 2026$270Mar 6, 2026$263Mar 20, 2026$274Apr 2, 2026$271Apr 17, 2026$256May 1, 2026$250May 15, 2026$260May 29, 2026$266Jun 12, 2026$271Jun 26, 2026$277Jul 10, 2026$297Jul 24, 2026$319Aug 7, 2026$336Aug 21, 2026$327Sep 4, 2026$321Sep 18, 2026$308Oct 2, 2026$318Oct 16, 2026$361Oct 30, 2026$370Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Labcorp Holdings (LH): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Moderate
Financial Safety Neutral
Valuation Moderate
Growth Durability Neutral
Momentum Strong

Legends Council

5 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Neutral
Revenue Growth Neutral
Debt/Equity Weak
ROE Neutral
Gross Margin Neutral

Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 17, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Labcorp Holdings (LH), and what does it report?

Short answer · as of

Labcorp processes clinical testing for patient care while also providing laboratory services used in pharmaceutical research and development.

Demand therefore comes from medical testing activity and drug-development programs, making the company broader than its diagnostics classification suggests.

Companywide revenue combines activities with different demand drivers. Lab Corp Diagnostics accounts for most disclosed segment revenue, while management separately discusses Central Labs and Early Development, so the consolidated result is not a pure measure of routine patient testing.

2 · Latest results

What do the latest results show for Labcorp Holdings (LH)?

The latest period extended revenue growth and produced stronger gross profit, operating profit, net income, and diluted earnings than the preceding period. Revenue and adjusted earnings also cleared market estimates, continuing a pattern in which adjusted earnings have exceeded expectations even when revenue occasionally missed.

Management maintained its free-cash-flow outlook and still expects Central Labs to grow faster than Early Development. That distinction matters: the reported improvement is visible in the financial statements, while the expected growth mix remains management guidance rather than an accomplished result.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$3.56B$261M$3.12 (diluted)
Q4 FY2025$3.52B$165M$1.98 (diluted)
Q1 FY2026$3.54B$278M$3.35 (diluted)
Q2 FY2026$3.73B$299M$3.64 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Labcorp Holdings (LH)?

Short answer

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

Labcorp remains profitable and has generated positive operating cash flow throughout the reported sequence, although conversion is uneven and recurring capital expenditure absorbs part of that cash. Liquidity ratios remain above parity, and the quality and distress screens are favorable.

The balance sheet carries substantial debt against a much smaller pool of cash and investments. Readily available cash has fallen sharply across the reported window, leaving operating cash generation more important to financial flexibility; the unchanged dividend also represents a continuing call on capital.

A slowdown in diagnostic activity or pharmaceutical laboratory work would pressure earnings while debt obligations and capital spending remain. That combination makes sustained cash conversion more consequential than an isolated earnings beat.

Data-derived red flags

  • Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
  • Rich valuation — a P/E of 30.01 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.
4 · What to check next?

What should you watch next at Labcorp Holdings (LH)?

Short answer · as of

The next earnings report is expected on Feb 16, 2027.

The upcoming earnings release should be read across revenue, gross profit, operating profit, and operating cash flow. Consensus implies modest sequential revenue progress but lower adjusted earnings than the latest reported comparison, so the quality of growth matters as much as clearing the headline estimates.

Watch whether cash rebuilds after its abrupt decline and whether operating cash flow covers capital expenditure with enough room to support debt and shareholder distributions. Progress in Central Labs alongside slower Early Development would align with management's stated mix; weakness across those laboratory activities would challenge it.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Labcorp Holdings compare with its peers?

Short answer

Labcorp Holdings's score ranks tied for 10th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Labcorp combines high-volume diagnostic services with laboratory work tied to pharmaceutical development. That gives it exposure to patient testing and research programs within the same company, unlike a business concentrated solely in routine clinical diagnostics or solely in outsourced drug-development work.

The trade-off is financial rather than merely operational: this breadth sits alongside meaningful leverage and limited cash relative to debt. Comparisons with similar laboratory businesses therefore need to account for service mix, cash conversion, and financing demands together.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
United Therapeutics Corporation (UTHR) Named competitor$577.34 Nov 18, 2026$24.6B97 5-pillar Nov 18, 2026
IDEXX Laboratories, Inc. (IDXX) Same industry, near in market value$698.47 Nov 18, 2026$55.0B96 5-pillar Nov 18, 2026
DexCom, Inc. (DXCM) Named competitor$82.52 Nov 18, 2026$30.8B93 5-pillar Nov 18, 2026
Mettler-Toledo International Inc. (MTD) Same industry, near in market value$1737.26 Nov 18, 2026$34.6B93 5-pillar Nov 18, 2026
Medpace Holdings, Inc. (MEDP) Same industry, near in market value$646.87 Nov 18, 2026$18.1B92 5-pillar Nov 18, 2026
STERIS plc (STE) Named competitor$259.57 Nov 18, 2026$25.2B87 5-pillar Nov 18, 2026
Illumina, Inc. (ILMN) Same industry, near in market value$210.01 Nov 18, 2026$31.8B84 5-pillar Nov 18, 2026
Agilent Technologies, Inc. (A) Same industry, near in market value$177.33 Nov 18, 2026$50.0B83 5-pillar Nov 18, 2026
Quest Diagnostics Incorporated (DGX) Named competitor$259.52 Nov 18, 2026$28.6B74 5-pillar Nov 18, 2026
Labcorp Holdings (LH) — this page$370.78$30.1B71
IQVIA Holdings Inc. (IQV) Same industry, near in market value$257.84 Nov 18, 2026$42.5B71 5-pillar Nov 18, 2026
Revvity, Inc. (RVTY) Same industry, near in market value$152.43 Nov 18, 2026$17.0B71 5-pillar Nov 18, 2026
Charles River Laboratories International, Inc. (CRL) Same industry, near in market value$333.25 Nov 18, 2026$16.0B70 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$355.00 – $420.00
Consensus target
$389.89
Median target
$395.00

Consensus record · Captured .

Measured against a quoted price of $370.78 (as of Nov 18, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 10, 2026

Transactions
29
Identified insiders
10
Purchases
0
Sales
11
Other transactions
18

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held LH in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported LH in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Labcorp Holdings (LH)?

Read these with our analysis →

Common Questions About LH (Healthcare)

The last 2 questions are answered from this page's own dated data, not from the research.

How does Labcorp make money from diagnostics and drug development?

Labcorp earns revenue by providing laboratory services for medical decision-making and for pharmaceutical research. Routine diagnostic activity and drug-development programs therefore feed different parts of the same operating platform.

Why can Labcorp revenue rise while its cash balance falls?

Revenue and accounting profit have increased, but cash also moves with operating conversion, capital expenditure, financing, distributions, and other uses. Recent operating cash flow remained positive while readily available cash contracted sharply, so earnings growth has not translated into cash accumulation.

What matters in Labcorp's Central Labs and Early Development outlook?

Management expects Central Labs to expand faster than Early Development. The relative performance of those activities will indicate whether growth is broad across pharmaceutical laboratory services or concentrated in the stronger operation.

What do Labcorp insider filings show about awards and sales?

Recent activity included sales and transactions classified as awards, in-kind movements, and exempt exercises, with no reported purchases. Those records describe transaction types but do not establish why an insider sold or received shares.

What is the LH stock price today?

The last price recorded for Labcorp Holdings Inc. (LH), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the LH price target?

The analyst consensus price target for Labcorp Holdings Inc. (LH), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 24 figures on this page — 1 from SEC filings and earnings calls, 19 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • Summary at the top of the page: Business description; Revenue by segment; Quarterly income statement (USD thousands); Cash, investments and debt; Cash and short-term investments over time (USD millions); Operating cash flow by quarter (USD millions)
  • 1. What is Labcorp Holdings (LH), and what does it report?: Sector / industry (provider taxonomy); Business description; Revenue by segment; Management outlook — dated call excerpts; Annual revenue and net result (USD millions)
  • 2. What do the latest results show for Labcorp Holdings (LH)?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Operating cash flow by quarter (USD millions); Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts
  • 3. What are the financial strengths and risks for Labcorp Holdings (LH)?: Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash decline over the reported window; Cash against market value; Trailing twelve-month ratio set; Distress and quality screens; Recent dividends paid; Business description; Management outlook — dated call excerpts
  • 4. What should you watch next at Labcorp Holdings (LH)?: Next earnings report; Reported versus estimated, last 8 quarters; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions); Cash, investments and debt; Recent dividends paid; Management outlook — dated call excerpts
  • 5. How does Labcorp Holdings compare with its peers?: Business description; Revenue by segment; Management outlook — dated call excerpts; Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash against market value; Trailing twelve-month ratio set
  • FAQ: How does Labcorp make money from diagnostics and drug development?: Business description; Revenue by segment; Management outlook — dated call excerpts
  • FAQ: Why can Labcorp revenue rise while its cash balance falls?: Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions); Cash decline over the reported window; Recent dividends paid
  • FAQ: What matters in Labcorp's Central Labs and Early Development outlook?: Management outlook — dated call excerpts
  • FAQ: What do Labcorp insider filings show about awards and sales?: Insider transactions, last 180 days; What the sources do not tell us
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold LH

Funds in our ETF coverage that list LH among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
IHF ETF4.05%
Allspring Special Large Value ETF (ASLV)3.08%